The microbiome is emerging as a key player in the effectiveness of CAR-T therapy, and today, Dr. Melody Smith, Assistant Professor of Medicine at Stanford University, sheds light on this fascinating intersection. Join us as we explore how advancements in CAR T-cell therapy are reshaping patient demographics and treatment approaches. Dr. Smith will discuss the implications of genetic engineering techniques like CRISPR, the importance of a multidisciplinary treatment strategy, and the role of antibiotic stewardship in optimizing outcomes. With insights into innovative therapies and ongoing clinical trials, this conversation promises to deepen your understanding of CAR-T therapy and its complexities, offering a glimpse into the future of cancer treatment.
Read Transcription
CME Information: https://stanford.cloud-cme.com/medcastepisode107
Claim CE: https://stanford.cloud-cme.com/Form.aspx?FormID=3392